Advances in Vaccines, Adjuvants and Delivery Technologies

Dear Colleagues,

The development of safe and effective vaccines is a key requirement to conquering pandemics and other infectious disease threats. After a surge in innovation approximately 50 years ago with the introduction of the first recombinant protein vaccines, polysaccharide conjugates vaccines and new adjuvants based on squalene oil emulsions and saponins, the field became relatively quiet in respect of new human vaccine technology innovations. This changed considerably with the COVID-19 pandemic, which has arguably resulted in the greatest number of new vaccine technology innovations introduced all in just a few years, with marketing approval given to COVID-19 vaccines embracing a wide variety of new technologies, including mRNA, DNA, and adenoviral vector delivery approaches, a range of new combination adjuvants, and the use of structural modeling approaches based on artificial intelligence and nanotechnology-based analytical techniques to design more stable vaccine antigens. The COVID-19 pandemic has emphasized the importance of innovation in the vaccine field. It is hoped that this current wave of innovation will develop more broadly in other vaccine programs, including those aimed at major ongoing challenges, including the development of new and improved vaccines against the likes of HIV, tuberculosis, and malaria, which remain major causes of global mortality, as well as to other fields in which vaccines might play an important role, such as vaccines against allergies, cancer, and Alzheimer’s disease. This Special Issue will spotlight these transformative vaccine innovations, highlighting the bright future which lies ahead for advancements in this field.

Prof. Dr. Nikolai Petrovsky
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.